Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    Atractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: The History Of Whoo Gongjinhyang Seol Whitening Sun
  2. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm

  3. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).

  4. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  5. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … [L48681] Toripalimab is a selective, recombinant, humanized IgG4 monoclonal antibody targeted against the PD-1 receptor.

    Categories: Programmed Death Receptor-1 Blocking Antibody
  6. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.

  7. Drug

    Thymol

    go.drugbank.com/drugs/DB02513
    ApprovedInvestigational

    A phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland,...

    Mixtures: Be Clean, Buenos Dias de Personna mint
  8. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. … Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].

  9. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. … Upon entry into the systemic circulation, the drug is partly oxidized and partly eliminated as an unchanged compound.

  10. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.